

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 5, 2022**

---

**The Joint Corp.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**001-36724**  
(Commission File Number)

**90-0544160**  
(I.R.S. Employer Identification No.)

**16767 N. Perimeter Drive, Suite 110  
Scottsdale, Arizona 85260**  
(Address of Principal Executive Offices) (Zip Code)

**(480) 245-5960**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 Par Value Per Share	JYNT	The NASDAQ Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

**Item 2.02. Results of Operations and Financial Condition.**

On May 5, 2022, The Joint Corp. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 7.01. Regulation FD Disclosure.**

The Company is posting an earnings presentation to its website at <https://ir.thejoint.com/>. A copy of the earnings presentation is being furnished herewith as Exhibit 99.2. The Company will use the earnings presentation during its earnings conference call on May 5, 2022 and also may use the earnings presentation from time to time in conversations with analysts, investors and others.

The information furnished in this Item 7.01 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The information contained in Exhibit 99.2 is summary information that is intended to be considered in the context of the Company’s filings with the SEC. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number	Description
<a href="#"><u>99.1</u></a>	<a href="#"><u>Press Release dated May 5, 2022</u></a>
<a href="#"><u>99.2</u></a>	<a href="#"><u>The Joint Corp. Earnings Presentation, May 2022</u></a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**The Joint Corp.**

Date: May 5, 2022

By: /s/ Peter D. Holt  
Peter D. Holt  
President and Chief Executive Officer

## The Joint Corp. Reports First Quarter 2022 Financial Results

- Grew Revenue 28%, System-wide Sales 27%, and System-wide Comp Sales 15%, Versus Q1 2021 -
- Opened 31 Clinics, Including 27 Franchised - the Most for a First Quarter in the Company's History -
- Achieved Milestone of 100 Corporate Portfolio Clinics, Bringing Total Clinics to 736 -

SCOTTSDALE, Ariz., May 05, 2022 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended March 31, 2022.

### Financial Highlights: Q1 2022 Compared to Q1 2021

- Grew revenue 28% to \$22.4 million.
- Recorded net loss of \$206,000, compared to net income of \$2.3 million.
- Increased system-wide sales<sup>1</sup> by 27%, to \$98.8 million.
- Reported system-wide comp sales<sup>2</sup> increase of 15%.
- Reported Adjusted EBITDA of \$1.8 million, compared to \$3.5 million.

### Recent Operating Highlights

- Sold 22 franchise licenses in Q1 2022, compared to 26 in Q1 2021.
- Increased total clinics to 736 at March 31, 2022, 636 franchised and 100 company-owned or managed, up from 706 at December 31, 2021.
  - Opened 27 new franchised clinics in Q1 2022, compared to 12 in Q1 2021.
  - Opened four greenfield clinics in Q1 2022, compared to one in Q1 2021.
  - Closed one franchised clinic in Q1 2022, compared to none in Q1 2021.
- Acquired the regional developer (RD) territory rights in Northern New Jersey in March for \$250,000 and in Northern California in April for \$2.4 million.

“During first quarter of 2022, we continued to drive growth, achieving the milestone of 100 corporate clinics and opening the most franchised clinics in any first quarter in the history of the company,” said Peter D. Holt, President and Chief Executive Officer of The Joint Corp. “While increasing labor costs and higher turnover impacted the entire system’s bottom line, the pace of our corporate clinic revenue growth was also impacted by the increasing magnitude and speed of the expansion of our corporate portfolio. Committed to executing our long-term growth strategy, we have added operational support to return the corporate portfolio to its strong trajectory, and we are implementing tactics to address today’s market. In forging the chiropractic dream, we are creating a more attractive environment to recruit and retain doctors of chiropractic. In harnessing the power of our data, we are finalizing our roadmap to create individualized and automated consumer marketing platforms. In accelerating the pace of clinic growth, we continue to improve our comprehensive franchise sales and clinic opening strategy. In fact, in March and April, we acquired rights to two regional developer territories, increasing our margin contribution within the franchise segment as well as creating the opportunity to open greenfield clinics in those regions. We are confident in our plan to overcome the near-term macro environment, build upon our strong foundation, and drive toward our goal of opening 1,000 clinics by the end of 2023.”

### Financial Results: First Quarter 2022 Compared to First Quarter 2021

Revenue was \$22.4 million in the first quarter of 2022, compared to \$17.6 million in the first quarter of 2021. The increase reflects a greater number of franchised and corporate clinics and continued organic growth. Cost of revenue was \$2.3 million, compared to \$1.8 million in the first quarter of 2021, reflecting the increased number of greenfield and franchised clinics, higher regional developer royalties and commissions, and the greater website hosting costs related to the new IT platform, which went live in July 2021.

Selling and marketing expenses were \$3.3 million, up 32%, driven by the larger number of franchised and company-owned or managed clinics, the grand opening expenses for four greenfields, and the timing of the national marketing fund spend as well as the new brand campaign.

Depreciation and amortization expenses increased for the first quarter of 2022, as compared to the prior year period, primarily due to the expenses associated with the new IT platform, previously acquired intangible assets and continued greenfield development.

General and administrative expenses were \$15.4 million, compared to \$10.1 million in the first quarter of 2021, reflecting increases in costs to support clinic growth, in payroll to remain competitive in the tight labor market, in professional fees, and in IT expenses.

Operating loss was \$176,000, including the impact of the accelerated greenfield development, higher G&A expenses, and higher depreciation and amortization. This compares to \$2.0 million of operating income in the first quarter of 2021. Income tax expense was \$13,000, compared to a benefit of \$364,000 in the first quarter of 2021. Net loss was \$206,000, or \$0.01 per share, compared to net income of \$2.3 million, or \$0.16 per diluted share, in the first quarter of 2021.

Adjusted EBITDA was \$1.8 million, compared to \$3.5 million in the first quarter of 2021. The company defines Adjusted EBITDA, a non-GAAP measure, as EBITDA before acquisition-related expenses, bargain purchase gain, net (gain)/loss on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net (loss) income before net interest, tax expense, depreciation, and amortization expenses.

### Balance Sheet Liquidity

Unrestricted cash was \$18.3 million at March 31, 2022, compared to \$19.5 million at December 31, 2021. During the quarter, the Company entered into an amendment to its Credit Facilities with JP Morgan. Under the 2022 Credit Facility, the revolving line of credit was increased to \$20 million, up from \$2 million. The revolver will be used for working capital needs, general corporate purposes and for acquisitions, development and capital improvement uses.

## 2022 Guidance

Management updated its revenue and Adjusted EBITDA guidance to reflect the impact of the macro-economic environment and the impact of increased expenses. Management reaffirmed its guidance for franchised clinic openings and company-owned or managed clinic increases.

- Revenue is now expected to be between \$98.0 million and \$102.0 million, compared to \$80.9 million in 2021.
- Adjusted EBITDA is now expected to be between \$12.0 million and \$14.0 million, compared to \$12.6 million in 2021.
- Franchised clinic openings are expected to be between 110 and 130, compared to 110 in 2021.
- Company-owned or managed clinic increases, through a combination of both greenfields and buybacks, are expected to be between 30 and 40; up from 32 added in 2021.

## Conference Call

The Joint Corp. management will host a conference call at 5 p.m. ET on Thursday, May 5, 2022, to discuss the first quarter 2022 financial results. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 765-507-2604 or 844-464-3931 and referencing code 5175957 approximately 15 minutes prior to the start time.

The accompanying slide presentation will be in the IR section of the website under Presentations and in Events. A live webcast of the conference call will also be available on the IR section of the company's website at <https://ir.thejoint.com/events>. An audio replay will be available two hours after the conclusion of the call for one week. The replay can be accessed by dialing 404-537-3406 or 855-859-2056. The passcode for the replay is 5175957.

## Commonly Discussed Performance Metrics

This release includes a presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

## Non-GAAP Financial Information

This release also includes a presentation of non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company's underlying operating performance and operating trends. Reconciliation of net income/(loss) to EBITDA and Adjusted EBITDA is presented in a table below. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, net (gain)/loss on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income before net interest, tax expense, depreciation, and amortization expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company's financial statements filed with the SEC.

## Forward-Looking Statements

This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand), inflation, exacerbated by COVID-19 and the current war in Ukraine, our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage, short-selling strategies and negative opinions posted on the internet which could drive down the market price of our common stock and result in class action lawsuits, our failure to remediate the current or future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence, and other factors described in our filings with the SEC, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 14, 2022 and subsequently-filed current and quarterly reports. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those

anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

Management has disclosed in our Form 10-K that our management concluded that our internal controls over financial reporting were not effective as of December 31, 2021, and our auditors expressed an adverse opinion on the Company's internal control over financial reporting as of December 31, 2021, due to a material weakness. The details of this material weakness were provided in our 10-K filing. We have undertaken remediation measures to address the material weakness, which we expect will be completed prior to the end of fiscal year 2022.

#### About The Joint Corp. (NASDAQ: JYNT)

The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation's largest operator, manager and franchisor of chiropractic clinics through *The Joint Chiropractic* network. The company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With more than 700 locations nationwide and nearly 11 million patient visits annually, *The Joint Chiropractic* is a key leader in the chiropractic industry. Ranked number one on *Forbes'* 2022 America's Best Small Companies list, number three on *Fortune's* 100 Fastest-Growing Companies list and consistently named to *Franchise Times* "Top 400+ Franchises" and *Entrepreneur's* "Franchise 500®" lists, *The Joint Chiropractic* is an innovative force, where healthcare meets retail.

For more information, visit [www.thejoint.com](http://www.thejoint.com). To learn about franchise opportunities, visit [www.thejointfranchise.com](http://www.thejointfranchise.com).

#### Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

**Media Contact:** Margie Wojciechowski, The Joint Corp., [margie.wojciechowski@thejoint.com](mailto:margie.wojciechowski@thejoint.com)

**Investor Contact:** Kirsten Chapman, LHA Investor Relations, 415-433-3777, [thejoint@lhainc.com](mailto:thejoint@lhainc.com)

#### – Financial Tables Follow –

#### THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES CONSOLIDATED BALANCE SHEETS (unaudited)

	March 31, 2022 (unaudited)	December 31, 2021
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 18,251,194	\$ 19,526,119
Restricted cash	594,717	386,219
Accounts receivable, net	3,612,802	3,700,810
Deferred franchise and regional development costs, current portion	985,557	994,587
Prepaid expenses and other current assets	2,426,409	2,281,765
Total current assets	25,870,679	26,889,500
Property and equipment, net	14,880,942	14,388,946
Operating lease right-of-use asset	18,927,052	18,425,914
Deferred franchise and regional development costs, net of current portion	5,601,142	5,505,420
Intangible assets, net	4,829,941	5,403,390
Goodwill	5,085,203	5,085,203
Deferred tax assets	9,205,410	9,188,634
Deposits and other assets	662,080	567,202
Total assets	\$ 85,062,449	\$ 85,454,209
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,874,911	\$ 1,705,568
Accrued expenses	1,644,709	1,809,460
Co-op funds liability	594,717	386,219
Payroll liabilities (\$0.7 million and \$0.4 million attributable to VIE)	2,383,977	3,906,317
Operating lease liability, current portion	4,872,292	4,613,843
Finance lease liability, current portion	34,479	49,855
Deferred franchise and regional developer fee revenue, current portion	3,130,856	3,191,892
Deferred revenue from company clinics (\$3.6 million and \$3.5 million attributable to VIE)	5,546,856	5,235,745
Other current liabilities	541,250	539,500

Total current liabilities	20,624,047	21,438,399
Operating lease liability, net of current portion	17,184,696	16,872,093
Finance lease liability, net of current portion	81,928	87,939
Debt under the Credit Agreement	2,000,000	2,000,000
Deferred franchise and regional developer fee revenue, net of current portion	15,410,136	15,458,921
Other liabilities	27,230	27,230
Total liabilities	55,328,037	55,884,582
Commitments and contingencies		
Stockholders' equity:		
Series A preferred stock, \$0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of March 31, 2022 and December 31, 2021	—	—
Common stock, \$0.001 par value; 20,000,000 shares authorized, 14,493,049 shares issued and 14,461,332 shares outstanding as of March 31, 2022 and 14,451,355 shares issued and 14,419,712 outstanding as of December 31, 2021	14,492	14,450
Additional paid-in capital	44,273,294	43,900,157
Treasury stock 31,717 shares as of March 31, 2022 and 31,643 shares as of December 31, 2021, at cost	(853,436)	(850,838)
Accumulated deficit	(13,724,938)	(13,519,142)
Total The Joint Corp. stockholders' equity	29,709,412	29,544,627
Non-controlling Interest	25,000	25,000
Total equity	29,734,412	29,569,627
Total liabilities and stockholders' equity	<u>\$ 85,062,449</u>	<u>\$ 85,454,209</u>

**THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES**  
**CONDENSED CONSOLIDATED INCOME STATEMENTS**  
(unaudited)

	<b>Three Months Ended March 31,</b>	
	<b>2022</b>	<b>2021</b>
Revenues:		
Revenues from company-owned or managed clinics	\$ 12,606,999	\$ 9,466,083
Royalty fees	6,008,932	4,769,246
Franchise fees	640,965	695,427
Advertising fund revenue	1,710,717	1,374,741
Software fees	956,998	760,537
Regional developer fees	201,787	217,956
Other revenues	312,140	263,975
Total revenues	<u>22,438,538</u>	<u>17,547,965</u>
Cost of revenues:		
Franchise and regional development cost of revenues	2,002,813	1,624,572
IT cost of revenues	309,958	140,745
Total cost of revenues	<u>2,312,771</u>	<u>1,765,317</u>
Selling and marketing expenses	3,287,488	2,489,279
Depreciation and amortization	1,629,176	1,169,866
General and administrative expenses	15,378,623	10,087,060
Total selling, general and administrative expenses	<u>20,295,287</u>	<u>13,746,205</u>
Net loss on disposition or impairment	6,906	64,767
(Loss) income from operations	<u>(176,426)</u>	<u>1,971,676</u>
Other expense, net	<u>(16,147)</u>	<u>(21,537)</u>
(Loss) income before income tax benefit	<u>(192,573)</u>	<u>1,950,139</u>
Income tax expense (benefit)	<u>13,224</u>	<u>(364,148)</u>
Net (loss) income	<u>\$ (205,797)</u>	<u>\$ 2,314,287</u>
Earnings per share:		
Basic (loss) earnings per share	\$ (0.01)	\$ 0.16
Diluted (loss) earnings per share	\$ (0.01)	\$ 0.16
Basic weighted average shares	14,432,652	14,178,542
Diluted weighted average shares	14,432,652	14,854,809

**THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(unaudited)

	<b>Three Months Ended March 31,</b>	
	<b>2022</b>	<b>2021</b>
Cash flows from operating activities:		
Net (loss) income	\$ (205,797)	\$ 2,314,287
Adjustments to reconcile net (loss) income to net cash provided by operating activities:		
Depreciation and amortization	1,629,176	1,169,866
Net loss on disposition or impairment (non-cash portion)	6,906	99,022
Net franchise fees recognized upon termination of franchise agreements	—	(69,702)
Deferred income taxes	(16,776)	(418,810)
Stock based compensation expense	323,556	246,494
Changes in operating assets and liabilities:		
Accounts receivable	88,008	(442,008)
Prepaid expenses and other current assets	(144,644)	(384,377)
Deferred franchise costs	(86,692)	(204,112)
Deposits and other assets	(94,878)	(3,313)
Accounts payable	59,461	(443,463)
Accrued expenses	(164,751)	60,493
Payroll liabilities	(1,522,340)	(217,020)
Deferred revenue	296,487	329,383
Other liabilities	280,162	234,708
Net cash provided by operating activities	447,878	2,271,448
Cash flows from investing activities:		
Purchase of property and equipment	(1,289,943)	(951,641)
Reacquisition and termination of regional developer rights	(250,000)	(1,388,700)
Net cash used in investing activities	(1,539,943)	(2,340,341)
Cash flows from financing activities:		
Payments of finance lease obligation	(21,387)	(18,238)
Purchases of treasury stock under employee stock plans	(2,598)	(618,154)
Proceeds from exercise of stock options	49,623	620,776
Repayment of debt under the Paycheck Protection Program	—	(2,727,970)
Net cash provided by (used in) financing activities	25,638	(2,743,586)
Decrease in cash, cash equivalents and restricted cash	(1,066,427)	(2,812,479)
Cash, cash equivalents and restricted cash, beginning of period	19,912,338	20,819,629
Cash, cash equivalents and restricted cash, end of period	\$ 18,845,911	\$ 18,007,150
Reconciliation of cash, cash equivalents and restricted cash:	<b>March 31, 2022</b>	<b>March 31, 2021</b>
Cash and cash equivalents	\$ 18,251,194	\$ 17,834,526
Restricted cash	594,717	172,624
	\$ 18,845,911	\$ 18,007,150

**THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES**  
**RECONCILIATION FOR GAAP TO NON-GAAP**  
(unaudited)

	<b>Three Months Ended March 31,</b>	
	<b>2022</b>	<b>2021</b>
<b>Non-GAAP Financial Data:</b>		
Net (loss) income	\$ (205,797)	\$ 2,314,287
Net interest expense	15,859	21,537
Depreciation and amortization expense	1,629,176	1,169,866
Tax expense (benefit)	13,224	(364,148)



EBITDA	1,452,462	3,141,542
Stock compensation expense	323,556	246,494
Acquisition related expenses	—	5,974
Loss on disposition or impairment	6,906	64,767
Adjusted EBITDA	<u>\$ 1,782,924</u>	<u>\$ 3,458,777</u>

---

<sup>1</sup> System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.

<sup>2</sup> Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.



The Joint Corp. | NASDAQ: JYNT | thejoint.com



## Q1 2022 Financial Results

As of March 31, 2022 | Reported on May 5, 2022

### Safe Harbor Statements

Certain statements contained in this presentation are "forward-looking statements" about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand), inflation, exacerbated by COVID-19 and the current war in Ukraine, our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage, short-selling strategies and negative opinions posted on the internet which could drive down the market price of our common stock and result in class action lawsuits, our failure to remediate the current or future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence, and other factors described in our filings with the SEC, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 14, 2022 and subsequently-filed current and quarterly reports. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

### Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.



# Three Enterprise Initiatives to Advance Growth

## Forging the Chiropractic Dream



## Harnessing the Power of Our Data



## Accelerating the Pace of Clinic Growth



© 2022 The Joint Corp. All Rights Reserved. | 3

# Building upon Foundation for Growth

# 27%

Increase in  
system-wide sales  
Q1 2022 over Q1 2021

# 15%

Increase in  
comp sales<sup>1</sup> for all clinics  
>13 months in operation  
Q1 2022 over Q1 2021

# 11%

Increase in  
comp sales<sup>1</sup> for all clinics  
>48 months in operation  
Q1 2022 over Q1 2021

	Q1 2022	Q1 2021
Revenue	\$22.4M	\$17.5M
Net (Loss)/Income	\$(206)K	\$2.3M
Adjusted EBITDA <sup>2</sup>	\$1.8M	\$3.5M
Unrestricted cash \$18.3M at March 31, 2022, compared to \$19.5M at December 31, 2021		



<sup>1</sup>Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed.

<sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.


| 4

# 27 Franchises Opened in Q1 2022, Highest for Any First Quarter

	Q1 2021	Q1 2022
Franchise Licenses Sold	26	22
Total New Franchised Clinics Opened	12	27
Greenfield Clinics Opened	1	4
Franchised Clinics Acquired	0	0
Clinics in Development	260	278

## TOTAL CLINICS OPEN

■ Franchise ■ Company Owned/Managed



© 2022 The Joint Corp. All Rights Reserved. | 5


## Franchise Licenses Sold Are Significant Pipeline

### Franchise Licenses Sold Annually




77% sold by RDs in Q1 2022

### Clinics in Active Development<sup>1</sup>



66% of clinics supported by 19 RDs as of April 1, 2022

### Gross Cumulative Franchise Licenses Sold<sup>1</sup>



RDs cover 55% of Metropolitan Statistical Areas (MSAs) as of April 1, 2022



<sup>1</sup> Of the 1,140 franchise licenses sold as of March 31, 2022, 278 are in active development, 737 are currently operating and the balance represents terminated/closed licenses.



# Investing in Brand Awareness

63+% of new patients influenced by online marketing in Q1 2022

Directing increased buying power to more sophisticated marketing programs

New video marketing and social media



7

# Enhancing Patient Experience and Efficiency through Improved Technology Infrastructure

## Initiatives

- Improvements to the user experience
- Enhanced promotional capabilities
- Advanced analytics
- Marketing automation
- Native mobile app
- Elevated risk control measures



**AXIS**   
Powered by The Joint Chiropractic



8

# Q1 2022 Financial Results

\$ in M <sup>1</sup>	Q1 2022	Q1 2021	Differences	
Revenue	\$22.4	\$17.6	\$4.9	28%
• Corporate clinics	12.6	9.5	3.1	33%
• Franchise fees	9.8	8.1	1.8	22%
Cost of revenue	2.3	1.8	0.5	31%
Sales and marketing	3.3	2.5	0.8	32%
Depreciation and amortization	1.6	1.2	0.4	39%
G&A	15.4	10.1	5.3	52%
Operating (Loss)/Income	(0.2)	2.0	(2.2)	(109)%
Tax Expense/(Benefit)	0.0	(0.4)	0.4	104%
Net (Loss)/Income	(0.2)	2.3	(2.5)	(109)%
Adj. EBITDA <sup>2</sup>	1.8	3.5	(1.7)	(48)%



<sup>1</sup> Due to rounding, numbers may not add up precisely to the totals.

<sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

© 2022 The Joint Corp. All Rights Reserved. | 9

## Updating 2022 Guidance

\$ in M	2021 Actual	2022 Low Guidance	2022 High Guidance
Revenues	\$80.9	\$98.0	\$102.0
Adjusted EBITDA <sup>1</sup>	\$12.6	\$12.0	\$14.0
New Franchised Clinic Openings	110	110	130
New Company-owned/Managed Clinics <sup>2</sup>	32	30	40



<sup>1</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the appendix.

<sup>2</sup> Through a combination of both greenfields and buybacks.

© 2022 The Joint Corp. All Rights Reserved. | 10

# Three Enterprise Initiatives to Advance Growth

## Forging the Chiropractic Dream



## Harnessing the Power of Our Data



## Accelerating the Pace of Clinic Growth



© 2022 The Joint Corp. All Rights Reserved. | 11


# Resilient Business Model Drives Long-term Growth

People will continue to seek more noninvasive, holistic ways to manage their pain.

**We'll be there to treat them.**

## The Joint Corp. 11-yr. CAGR 67%<sup>1</sup> vs. Industry CAGR 5.4%<sup>2\*</sup>

System-wide Sales  
(\$ in M)



<sup>1</sup> For the period ended Dec. 31, 2021 | <sup>2</sup> June 2021 Kentley Insights Chiropractic Care Market Research Report

| 12

# Performance Metrics and Non-GAAP Measures

This presentation includes commonly discussed performance metrics. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

This presentation includes non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends than GAAP measures alone. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase net gain, gain/(loss) on disposition or impairment, and stock-based compensation expenses.


EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.



13

## Q1 2022 Segment Results

\$ in 000s



Total Revenues	\$ 12,607
Total Operating Costs	(13,045)
Operating Income (Loss)	(438)
Other Income (Expense), net	(1)
Loss Before Income Tax Expense	(439)
Total Income Taxes	-
Net Income (Loss)	(439)
Net Interest	1
Income Taxes	-
Total Depreciation and Amortization Expense	1,376
EBITDA	938
Stock Based Compensation Exp	-
Bargain Purchase Gain	-
(Gain) Loss on Disposition/Impairment	7
Acquisition Expenses	-
Adjusted EBITDA	945

Corporate Clinics	Franchise Operations	Unallocated Corporate	The Joint Consolidated
\$ 12,607	\$ 9,831	\$ 0	\$ 22,439
(13,045)	(5,428)	(4,142)	(22,615)
(438)	4,403	(4,142)	(176)
(1)	-	(15)	(16)
(439)	4,403	(4,156)	(193)
-	-	13	13
(439)	4,403	(4,170)	(206)
1	-	15	16
-	-	13	13
1,376	173	79	1,629
938	4,577	(4,062)	1,453
-	-	324	324
-	-	-	-
7	-	-	7
-	-	(0)	(0)
945	4,577	(3,739)	1,783



14



# GAAP – Non-GAAP Reconciliation

\$ in 000s

	Quarter Ending 03/31/2020	Quarter Ending 06/30/2020	Quarter Ending 09/30/2020	Quarter Ending 12/31/2020		Quarter Ending 03/31/2021	Quarter Ending 06/30/2021	Quarter Ending 09/30/2021	Quarter Ending 12/31/2021		Quarter Ending 03/31/2022				
	Q1-20	Q2-20	Q3-20	Q4-20	FY20	Q1-21	Q2-21	Q3-21	Q4-21	FY21	Q1-22	Q2-22	Q3-22	Q4-22	FY22
Total Revenue	13,644	12,590	15,411	17,038	58,683	17,548	20,219	20,992	22,101	80,860	22,439	-	-	-	22,439
Total Cost of Revenue	1,486	1,368	1,712	1,941	6,507	1,765	2,039	2,300	2,410	8,514	2,313	-	-	-	2,313
<b>Gross Profit</b>	<b>\$ 12,158</b>	<b>\$ 11,222</b>	<b>\$ 13,698</b>	<b>\$ 15,097</b>	<b>\$ 52,176</b>	<b>\$ 15,783</b>	<b>\$ 18,180</b>	<b>\$ 18,691</b>	<b>\$ 19,691</b>	<b>\$ 72,346</b>	<b>\$ 20,126</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 20,126</b>
Sales & Marketing	2,055	1,784	1,846	2,120	7,804	2,489	3,133	2,882	2,921	11,424	3,287	-	-	-	3,287
Depreciation/Amortization Expense	654	693	714	673	2,734	1,170	1,443	1,662	1,814	6,089	1,629	-	-	-	1,629
Other Operating Expenses	8,695	8,487	9,433	9,527	36,142	10,186	11,611	12,812	14,936	49,546	15,379	-	-	-	15,379
Total Other Income (Expense)	(4)	(25)	(26)	(26)	(82)	13	25	(13)	(29)	(4)	(23)	-	-	-	(23)
Total Income Taxes	(66)	118	76	(7,882)	(7,755)	(364)	(666)	(614)	351	(1,293)	13	-	-	-	13
<b>Net Income (Loss)</b>	<b>\$ 815</b>	<b>\$ 116</b>	<b>\$ 1,604</b>	<b>\$ 10,633</b>	<b>\$ 13,167</b>	<b>\$ 2,315</b>	<b>\$ 2,684</b>	<b>\$ 1,937</b>	<b>\$ (360)</b>	<b>\$ 6,576</b>	<b>\$ (206)</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ (206)</b>
Net Interest	4	25	26	24	79	22	16	16	16	70	16	-	-	-	16
Income Taxes	(66)	118	76	(7,882)	(7,755)	(364)	(666)	(614)	351	(1,293)	13	-	-	-	13
Depreciation and Amortization Expense	654	693	714	673	2,734	1,170	1,443	1,662	1,814	6,089	1,629	-	-	-	1,629
<b>EBITDA</b>	<b>\$ 1,408</b>	<b>\$ 952</b>	<b>\$ 2,420</b>	<b>\$ 3,447</b>	<b>\$ 8,227</b>	<b>\$ 3,142</b>	<b>\$ 3,477</b>	<b>\$ 3,001</b>	<b>\$ 1,821</b>	<b>\$ 11,441</b>	<b>\$ 1,453</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 1,453</b>
Stock Based Compensation	250	216	212	207	886	246	284	297	229	1,056	324	-	-	-	324
Bargain Purchase Gain	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Gain) Loss on Disposition/Impairment	1	(55)	-	2	(51)	65	(44)	(4)	10	27	-	-	-	-	-
Acquisition Expenses	-	-	-	42	42	6	39	3	20	69	(0)	-	-	-	(0)
<b>Adjusted EBITDA</b>	<b>\$ 1,659</b>	<b>\$ 1,113</b>	<b>\$ 2,632</b>	<b>\$ 3,698</b>	<b>\$ 9,103</b>	<b>\$ 3,459</b>	<b>\$ 3,756</b>	<b>\$ 3,297</b>	<b>\$ 2,080</b>	<b>\$ 12,593</b>	<b>\$ 1,783</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 1,783</b>



15

## The Joint Corp. Contact Information



**Peter D. Holt, President and CEO**

[peter.holt@thejoint.com](mailto:peter.holt@thejoint.com)

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



**Jake Singleton, CFO**

[jake.singleton@thejoint.com](mailto:jake.singleton@thejoint.com)

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



**Kirsten Chapman, LHA Investor Relations**

[thejoint@lhai.com](mailto:thejoint@lhai.com)

LHA Investor Relations | One Market Street, Spear Tower, Suite 3600, San Francisco, CA 94105 | (415) 433-3777



[@thejointchiro](https://www.facebook.com/thejointchiro)



[@thejointchiro](https://twitter.com/thejointchiro)



[@thejointcorp](https://www.youtube.com/thejointcorp)



© 2022 The Joint Corp. All Rights Reserved. 16